<DOC>
	<DOC>NCT00328705</DOC>
	<brief_summary>This is an acute, prospective, multi-center, non-randomized, investigational device exemption (IDE) clinical study.</brief_summary>
	<brief_title>D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management</brief_title>
	<detailed_description>The purpose of this study is to confirm the performance of new sensing circuitry, and to confirm the performance of a Ventricular Capture Management feature in subjects with implantable cardioverter defibrillator (ICD) leads connected to an external pacemaker/defibrillator.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>Patients who are scheduled for implantation or replacement of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device Patients must have or receive Medtronic transvenous atrial and ventricular leads in association with the scheduled device implant or replacement. Patients who have 3rd degree heart block, as assessed by the investigator Patients who have a mechanical tricuspid heart valve Patients who have received an investigational new drug or device, or are currently enrolled in a clinical study for a new indication of an approved drug or device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Sensing</keyword>
	<keyword>Capture Management</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>ICD Indication</keyword>
</DOC>